- Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). BE j Cancer 84\(Suppl. 1), 3–10 (2001).
- Demetri GD. Anemia and its functional consequences in cancer patients: current challenges im. management and prospects for improving therapy. BE j Cancer 84, (Suppl. 1), 31–37 (2001).
- ••A brief, but clear and comprehensivepresentation of the problems engendered by anemia in cancer patients and of the current and possible future treatment options.
- Moliterno AR, Spivak JL. Anemia in cancer. Hematol Oncol Clin. North Am.10,346–363 (1995).
- DeVita VT, Hellmann S, Rosenberg SA. Cancer: Principles and practice of oncology 4th Edition, Lippincott, Philadelphia, USA (1993).
- Agency for Healthcare Research and Quality. Uses of epoetin for anemia in oncology. Evidence Report/Technology Assessment No. 30, AHRQ Publication Number 01-E008, Rockville, USA (2001).
- Bottomley A. Measuring quality of life in the anemic cancer patient. In: Anemia in cancer Bokemeyer C, Ludwig H. (Eds). ESO Scientific Updates vol. 6, Elsevier, Oxford, UK. 55–66 (2001).
- Goodnough LT, Brecher ME, Kanter MET et al Transfusion medicine. First of two parts - Blood transfusions. N Engl. I Med340,438–447 (1999).
- Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood97,1180–1195 (2001).
- Seidenfeld J, Piper M, Flamm C etal Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. j Natl. Cancer Ins 93,1204-1214 (2001).A careful and methodically well-founded systematic review and meta-analysis of the use of epoetin against anemia in cancer patients.
- Beguin Y. Prediction of response to rHuEPO. In: Anemia in cancer Bokemeyer C, Ludwig H. (Eds). ESO Scientific Updates vol. 6, Elsevier, Oxford, 153–166 (2001).
- Sheffield R, Sullivan SD, Saltiel E,Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann. Pharmacother 31, 15–22 (1997).
- Littlewood T The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin. Oncol 28\(Suppl. 8), 49–53 (2001).
- Neymark N. Pharmacoeconomic analyses of the use of rHuEPO in chemotherapy-induced anemia of cancer patients. In: Anemia in cancer Bokemeyer C, Ludwig H. (Eds). ESO Scientific Updates vol. 6, Elsevier, Oxford, UK. 189–205 (2001).
- Barosi G, Liberato NL. The cost- effectiveness of rhEPO use in anemia of cancer. In: rliBythropoetin in Cancer Supportive Treatment, Smith JF, Boogaerts MA, Ehmer BRM (Eds.) Marcel Dekker, New York, USA (1996).
- Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. BE Cancer78, 781–787 (1998).
- Drummond ME, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BE Med. 1. 313, 275–283 (1996).
- Meadowcroft AM, Gilbert CJ, Maravich-May D, Hayward SL. Costs of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy. Am. j Health Syst. 55,1898–1902 (1998).
- Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB. Cost-effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. PharmacoEconomics 16,459–472 (1999).
- Abels RI, Larhot KM, Krantz KD, BryantEC. Recombinant human erythropoetin (r-huEPO) for the treatment of anemia incancer. In: Blood cell growth factors: their present, and future use in hematology and oncology Proceedings of the Beying Symposium. Murphy MJ (Ed.) Alpha Med. Press, Ohio, USA 121–141 (1991).
- Ortega A, Dranitsaris G, Puodziunas ALV. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. Cancer 83,2588–2596 (1998).
- •Cost-benefit analysis using state-of-the-art methods for elicitation of willingness-to-pay and determining net benefits of the use of epoetin in cancer patients with severe anemia.
- Cremieux PY, Barrett B, Anderson K etal Cost of out-patient blood transfusion in cancer patients. j Clin. Oncol 18,2755–2761 (2000).
- Barosi G, Marchetti M. The clinical utility of epoetin in cancer patients: a matter of perspective. I-Lematologica 85,449–450 (2000).
- Cleeland CS, Demetri GD, Glaspy J etal Identifying hemoglobin level for optimal quality of life: an incremental analysis. ASCO Proceedings 18(574a), 2215 (1999).
- Bottomley A, Thomas R, van Steen K etal.Human recombinant erythropoietin and quality of life: A wonder drug or something to wonder about? Lancet Oncology (In Press).
- Littlewood TJ, Bajetta E, Nortier JWR etal Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. Clin. Oncol 19,2865–2874 (2001).
- Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 91, 2214–2221 (2001).
- Höckel M, Vaupel P Biological consequences of tumor hypoxia. Semin. Oncol 28\(Suppl. 8), 36–41 (2001).
- Höckel M, Vaupel P Tumor hypoxia: definitions and current clinical, biologic and molecular aspects. j Natl. Can. Ins. 93, 266–276 (2001).
- Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron and erythropoiesis. B/ooc/96,823–833 (2000).
Assessment of the economic value of epoetin use in anemic cancer patients
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.